Entyvio (vedolizumab) is a first-in-class, gut-selective biologic treatment for moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.1LEARN MORE
The safety and efficacy of Entyvio is supported by the results of the GEMINI™ Studies.1-4 These four phase III studies involved 2,400 individuals with UC or CD who were recruited from nearly 40 countries. GEMINI is the largest phase III clinical trial programme to date that evaluated a new treatment for UC or CD concurrently.LEARN MORE
Takeda Pharmaceutical Company Limited has a long history in the research and development, manufacturing, sales and marketing, and import/export of pharmaceutical products. The corporate mission to “strive towards better health for people worldwide through leading innovation in medicine” has led to the development of several state-of-the-art medicines, including Entyvio for UC and CD.LEARN MORE
In Risk Management Materials there are a number of important documents available for you to download including the Patient Alert Card (PAC), Healthcare Professional (HCP) Guide, Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL). In addition, in the Info & Support section you can access other useful resources, information and links to Patient Support Groups who can provide further help and advice for your patients.LEARN MORE
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Any adverse events observed following the prescription of Entyvio ▼ should be reported. In the United Kingdom, adverse event reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.